Close Menu

Brandi Davis-Dusenbery

Mar 15, 2017

Seven Bridges has promoted Brandi Davis-Dusenbery to CEO. She succeeds Co-founder Deniz Kural, who is assuming the role of executive chairman of the board of directors. Davis-Dusenbery was the former senior vice president of science and product for Seven Bridges. Prior to Seven Bridges, she worked as a fellow at Harvard University's Department of Stem Cell and Regenerative Biology.

More Like This

Dec 06, 2019

Bionano Genomics: Quan Zhou

Quan Zhou resigned from the Bionano Genomics board of directors, effective Dec. 12. In a document filed Dec. 6 with the US Securities and Exchange Commission, Bionano Genomics said the resignation "is not the result of any disagreement with the company." 

Dec 06, 2019

Insitro: Serafim Batzoglou

Serafim Batzoglou has become chief data officer of San Francisco-based drug discovery and development firm Insitro. He joins the company from Illumina, where he was VP of applied and computational biology. Prior to that, he was a professor of computer science at Stanford University. He is also a cofounder of DNAnexus. Batzoglou holds a PhD in computer science, a master's degree in electrical engineering, and a BS in mathematics and computer science from MIT.

Dec 06, 2019

Centogene: Philip Lambert, Peter Bauer

Philip Lambert has become CSO of Centogene, replacing Peter Bauer, who is now the firm's chief genomic officer. Lambert joins the company from Life Biosciences, where he was senior VP of discovery and labs as well as chief operating officer of two subsidiaries, Selphagy Therapeutics and Spotlight Biosciences. Prior to that, he was scientific partner and head of discovery at Charles River Laboratories. He also cofounded preclinical screening firm VivoPath. Lambert holds a PhD in neuropharmacology from Imperial College London and a BSc in pharmacology from the University of Liverpool.

Dec 02, 2019

NeoGenomics: Lawrence Weiss

NeoGenomics has appointed Lawrence Weiss as the company's chief medical officer, effective Nov. 25. He has been NeoGenomics' CSO since December 2018. Prior to that, he had been the firm's director of pathology services since March 2016. Before joining NeoGenomics, Weiss was a pathologist and later laboratory director at Clarient Diagnostic Services.

Dec 02, 2019

Bionano Genomics: Mike Ward

Bionano Genomics CFO Mike Ward has notified the firm of his resignation, effective Dec. 6. "Ward's resignation is not the result of any disagreement with the company," Bionano Genomics said last week in a document filed with the US Securities and Exchange Commission.

Nov 22, 2019

Inteliquet: Marie Lamont

Inteliquet has named Marie Lamont interim president and chief operating officer. She replaces former CEO, President, and COO Carla Balch, who left Inteliquet to "pursue other opportunities," the company said. Lamont had been president of patient services at Dolman Life Science Services. Previously, she held several senior positions at Genzyme. Inteliquet rebranded from TransMed Systems earlier this year.

Nov 21, 2019

NYGC: Mary-Claire King

Mary-Claire King has joined the New York Genome Center faculty on a consulting basis as a senior associate core member. She is the American Cancer Society Professor in the Department of Genome Sciences and Medicine at the University of Washington in Seattle. At the NYGC, she will work closely with Thomas Lehner, the center's recently appointed scientific director of neuropsychiatric disease, and act as a senior adviser to both Lehner and Tom Maniatis, the center's CEO.  

Nov 21, 2019

Elucidata: Richard Kibbey, Nick Pullen, Avi Ma'ayan

Elucidata has formed a scientific advisory board comprising Richard Kibbey, Nick Pullen, and Avi Ma'ayan. Kibbey is associate professor of medicine (endocrinology) and cellular & molecular biology at the Yale School of Medicine. Pullen is the scientific cofounder of Elucidata, and has more than 20 years of experience in the pharmaceutical industry with Pfizer, Roche, and most recently Celgene. Ma'ayan is director of the Mount Sinai Center for Bioinformatics and a professor of bioinformatics in Mount Sinai's Department of Pharmacological Sciences.

Nov 20, 2019

Twist Bioscience: Patrick Finn

Patrick Finn has been promoted from senior VP of commercial operations to chief operating officer of Twist Bioscience, a new position at the company. Prior to joining Twist in 2015, Finn was VP of sales at Enzymatics, and before that, he held various positions at Agilent Technologies, Beckman Coulter, Invitrogen, and GE Healthcare/Amersham International. He holds a PhD in nucleic acid chemistry from the University of Southampton in England and a BSc in chemistry from Heriot-Watt University in Scotland.

Nov 20, 2019

GenapSys: Frank Witney, Rakesh Sachdev, Hamid Moghadam

In connection with its recent funding round, GenapSys has made several appointments to its board of directors. Joining the board are Frank Witney, former CEO of Affymetrix and Dionex; Rakesh Sachdev, former CEO of Sigma Aldrich and Platform Specialty Products; and Hamid Moghadam, CEO and chairman of Prologis.

Nov 20, 2019

BioTeam: Ari Berman, Stan Gloss

Ari Berman has been promoted from VP of consulting to CEO of BioTeam. He replaces company cofounder Stan Gloss, who will become BioTeam's chief marketing officer. Berman holds a PhD in molecular biology from the University of Texas at Austin.

Nov 20, 2019

ATCC: Raymond Stapleton

Raymond Stapleton has been appointed as president and chief operating officer of biological materials resource and standards organization ATCC. Previously, he was senior VP of technical operations at Iovance Biotherapeutics, and before that, he held various roles at Merck. Stapleton holds a PhD in microbial ecology from the University of Tennessee and a bachelor's degree in biology from Mary Washington College in Fredericksburg, Virginia.

Nov 20, 2019

Sophia Genetics: Milton Silva-Craig

Sophia Genetics has named Milton Silva-Craig to its board of directors. Silva-Craig currently serves as CEO of Q-Centrix, a maker of healthcare data management technology. He previously headed the healthcare business unit of TransUnion and was president and CEO of Emageon, a health imaging software company that he helped lead through an initial public offering before that firm was sold to revenue-cycle management technology vendor Health Systems Solutions.

Nov 14, 2019

SEngine Precision Medicine: Astrid Margossian

SEngine Precision Medicine has hired Astrid Margossian as chief medical officer. Margossian, a surgeon, medical oncologist, and cancer researcher with MD and PhD degrees, previously established and served as medical director of Baylor College of Medicine's Breast Center Buenos Aires and Breast Cancer Research Biobank, which focuses on biomarker discovery for breast cancer. 

Nov 14, 2019

Sema4: Joel Sendek

Sema4 has appointed Joel Sendek as chief financial officer.

Sendek brings more than 25 years of financial experience in the pharmaceutical and biotechnology sector, including overseeing successful initial public offerings at his last two companies.

Previously, Sendek was CFO at Spero Therapeutics and Forward Pharma. He spent more than 15 years as an equities research analyst at Stifel Financial and Lazard, worked in corporate development at Progenics Pharmaceuticals, and was an investment banking analyst at Goldman Sachs. He holds a BA in biochemistry from Rice University.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.